Female cancer survivors more likely to report cost-related non-adherence
the ONA take:
Significant gender differences in cost-related medication non-adherence (CRN) were found among cancer survivors after adjusting for differences in sociodemographic, health status, and insurance coverage, a new study published online ahead of print in the Journal of Cancer Survivorship.
Because it has been reported that cancer survivors delay or avoid necessary care due to costs, researchers sought to determine the prevalence of CRN by gender and other factors among cancer survivors.
For the study, researchers from the University of South Carolina Arnold School of Public Health, in Columbia, analyzed data from 15,159 cancer survivors. Of those, 7.4% of male and 12.5% of female survivors reported CRN.
Results showed that female cancer survivors were 27% more likely than males to report CRN. Researchers found that a higher number of comorbidities and activity limitations were associated with higher CRN rates for both males and females.
“Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups,” the authors conclude.
Significant gender differences in cost-related medication non-adherence were found among cancer survivors.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- The Integration of Cannabis in Oncologic Care
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|